Kelsey L Richardson1, Donald J Weaver2, Derek K Ng3, Megan K Carroll3, Susan L Furth4, Bradley A Warady5, Joseph T Flynn6. 1. Division of Pediatric Nephrology, Oregon Health & Sciences University, Portland, OR, USA. 2. Pediatric Nephrology and Hypertension, Atrium Health Levine Children's, 1000 Blythe Blvd, Str 200, Charlotte, NC, 28232, USA. Jack.weaver@atriumhealth.org. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Division of Pediatric Nephrology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 5. Division of Pediatric Nephrology, Children's Mercy Hospital, Kansas City, MO, USA. 6. Department of Pediatrics, University of Washington; Division of Nephrology, Seattle Children's Hospital, Seattle, WA, USA.
Abstract
BACKGROUND: Hypertension is common among children with chronic kidney disease (CKD), and dihydropyridine calcium channel blockers (dhCCBs) are frequently used as treatment. The impact of dhCCBs on proteinuria in children with CKD is unclear. METHODS: Data from 722 participants in the Chronic Kidney Disease in Children (CKiD) longitudinal cohort with a median age of 12 years were used to assess the association between dhCCBs and log transformed urine protein/creatinine levels as well as blood pressure control measured at annual visits. Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) use was evaluated as an effect measure modifier. RESULTS: Individuals using dhCCBs had 18.8% higher urine protein/creatinine levels compared to those with no history of dhCCB or ACEi and ARB use. Among individuals using ACEi and ARB therapy concomitantly, dhCCB use was not associated with an increase in proteinuria. Those using dhCCBs had higher systolic and diastolic blood pressures. CONCLUSIONS: Use of dhCCBs in children with CKD and hypertension is associated with higher levels of proteinuria and was not found to be associated with improved blood pressure control.
BACKGROUND: Hypertension is common among children with chronic kidney disease (CKD), and dihydropyridine calcium channel blockers (dhCCBs) are frequently used as treatment. The impact of dhCCBs on proteinuria in children with CKD is unclear. METHODS: Data from 722 participants in the Chronic Kidney Disease in Children (CKiD) longitudinal cohort with a median age of 12 years were used to assess the association between dhCCBs and log transformed urine protein/creatinine levels as well as blood pressure control measured at annual visits. Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) use was evaluated as an effect measure modifier. RESULTS: Individuals using dhCCBs had 18.8% higher urine protein/creatinine levels compared to those with no history of dhCCB or ACEi and ARB use. Among individuals using ACEi and ARB therapy concomitantly, dhCCB use was not associated with an increase in proteinuria. Those using dhCCBs had higher systolic and diastolic blood pressures. CONCLUSIONS: Use of dhCCBs in children with CKD and hypertension is associated with higher levels of proteinuria and was not found to be associated with improved blood pressure control.
Authors: Sahar A Fathallah-Shaykh; Joseph T Flynn; Christopher B Pierce; Alison G Abraham; Tom D Blydt-Hansen; Susan F Massengill; Marva M Moxey-Mims; Bradley A Warady; Susan L Furth; Craig S Wong Journal: Clin J Am Soc Nephrol Date: 2015-01-29 Impact factor: 8.237
Authors: Sophie M van den Belt; Hiddo J L Heerspink; Marietta Kirchner; Valentina Gracchi; Daniela Thurn-Valsassina; Aysun K Bayazit; Anna Niemirska; Nur Canpolat; Ipek Kaplan Bulut; Karolis Azukaitis; Ali Duzova; Justine Bacchetta; Rukshana Shroff; Dusan Paripovic; Zeynep Birsin Özçakar; Kibriya Fidan; Hakan Erdogan; Jutta Gellermann; Elke Wühl; Dick de Zeeuw; Anette Melk; Uwe Querfeld; Franz Schaefer Journal: Clin J Am Soc Nephrol Date: 2020-04-06 Impact factor: 8.237
Authors: Bradley A Warady; Alison G Abraham; George J Schwartz; Craig S Wong; Alvaro Muñoz; Aisha Betoko; Mark Mitsnefes; Frederick Kaskel; Larry A Greenbaum; Robert H Mak; Joseph Flynn; Marva M Moxey-Mims; Susan Furth Journal: Am J Kidney Dis Date: 2015-03-19 Impact factor: 8.860
Authors: Elke Wühl; Antonella Trivelli; Stefano Picca; Mieczyslaw Litwin; Amira Peco-Antic; Aleksandra Zurowska; Sara Testa; Augustina Jankauskiene; Sevinc Emre; Alberto Caldas-Afonso; Ali Anarat; Patrick Niaudet; Sevgi Mir; Aysin Bakkaloglu; Barbara Enke; Giovanni Montini; Ann-Margret Wingen; Peter Sallay; Nikola Jeck; Ulla Berg; Salim Caliskan; Simone Wygoda; Katharina Hohbach-Hohenfellner; Jiri Dusek; Tomasz Urasinski; Klaus Arbeiter; Thomas Neuhaus; Jutta Gellermann; Dorota Drozdz; Michel Fischbach; Kristina Möller; Marianne Wigger; Licia Peruzzi; Otto Mehls; Franz Schaefer Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: Susan L Furth; Stephen R Cole; Marva Moxey-Mims; Frederick Kaskel; Robert Mak; George Schwartz; Craig Wong; Alvaro Muñoz; Bradley A Warady Journal: Clin J Am Soc Nephrol Date: 2006-07-19 Impact factor: 8.237
Authors: Amy J Kogon; Christopher B Pierce; Christopher Cox; Tammy M Brady; Mark M Mitsnefes; Bradley A Warady; Susan L Furth; Joseph T Flynn Journal: Kidney Int Date: 2013-09-18 Impact factor: 10.612
Authors: Valerie A Luyckx; Andrew D Rule; Katherine R Tuttle; Pierre Delanaye; Helen Liapis; Afschin Gandjour; Paola Romagnani; Hans-Joachim Anders Journal: Nat Rev Nephrol Date: 2021-12-08 Impact factor: 42.439